#ASH16: Pfiz­er of­fers a thumbs-up on OS da­ta from PhII blood can­cer study of glas­deg­ib

Pfiz­er came up with some solid­ly pos­i­tive Phase II da­ta for a new drug that’s de­signed to throw a mon­key wrench in­to the bi­ol­o­gy dri­ving the hedge­hog path­way in acute myeloid leukemia.

In­ves­ti­ga­tors said that glas­deg­ib, an oral SMO in­hibitor ini­tial­ly cod­ed PF-04449913, sig­nif­i­cant­ly in­creased the over­all sur­vival of a group of pa­tients tak­ing the drug in com­bi­na­tion with low-dose cy­tara­bine (LDAC) com­pared to LDAC alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER